Fecal Microbiota Transplantation Superior to Fidaxomicin for Recurrent C Difficile Infection
Data from a study presents compelling evidence for the superiority of FMT in multiply recurrent CDI.
Clostridioides Difficile
Clostridioides difficile
Feature Article
Latest News
Changes in Microbiota Predictive of Recurrent C Difficile Infection Risk
Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
Glutamate Dehydrogenase Test Reduces Isolation for C difficile Infection
A glutamate dehydrogenase test for Clostridioides difficile may reduce unnecessary isolation time for patients.
Fidaxomicin Approved for C difficile-Associated Diarrhea in Pediatric Patients
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Prevalence and Length of Hospital Stay for Clostridioides difficile Infections
Clostridioides difficile infection is associated with a large burden on the healthcare system in the United States.
Dual Therapy for C difficile Infection Not Superior to Vancomycin Alone
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
One in 10 Hospital Patients May Carry C difficile at Admission
Asymptomatic carriers of C. difficile at significant risk for progression to symptomatic infection
Toxin Enzyme Immunoassay Identifies Severe Clostridioides difficile Infections
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.
Incidence of Bloodstream Infections Lower in Recurrent CDI With Fecal Transplant
Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Latest Evidence and Clinical Guidance to Reduce Clostridioides difficile Infection Recurrence
Studies present promising therapeutic options to reduce recurrent CDI, as well as strategies to improve favorable economic outcomes.
Detection of Fecal C difficile Toxins of High Importance in Diagnosis
Detection of Clostridioides difficile toxins in fecal matter can lead to accurate diagnosis of C difficile infection.
Substantial Costs Attributable to Hospital-Acquired C Difficile
Direct costs come from extended length of stay and increased hospitalization costs
Best Laboratory Practices for Clostridioides difficile Diagnosis in Adults
Repeat testing of nucleic acid amplification tests is not recommended for detection of the presence of Clostridioides (formerly Clostridium) difficile in adults.
Effect of Diagnostic Test on Hospital Length of Stay for Patients with C difficile
The use of a nucleic acid assay (NAAT) for diagnosing Clostridium difficile infection demonstrated a significant reduced length of stay (LOS) for patients compared with a multi-step enzyme immunoassay-based strategy, according to data presented at the American Society for Microbiology (ASM) Microbe 2019, held in San Francisco, California, from June 20 to 24, 2019. C…
FDA Warns of Infections From Fecal Transplants After One Death
Fecal microbiota transplantation is a still-experimental procedure, as yet unapproved by the FDA
Incidence of C Difficile Infection Lowered With Decreased Antibiotic Usage
Facility-level rates of hospital-onset Clostridioides difficile infection have been found to decrease correspondingly with lower usage of antibiotics.
Fecal Microbiota Transplantation and Vancomycin for Recurrent C difficile
The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin for patients with recurrent CDI.
CP101 Designated Breakthrough Tx for Recurrent C difficile Infection
The FDA has granted Breakthrough Therapy designation to CP101 for the treatment of patients with recurrent Clostridium difficile.
FDA Approves New Treatment for Travelers’ Diarrhea
Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.
Oral Vancomycin May Prevent Clostridioides Difficile Infection in Transplant Recipients
Oral vancomycin is effective in preventing C difficile infection in allogeneic hematopoietic cell transplant patients and does not raise the risk for GVHD.
Clostridioides difficile Infection Increases Likelihood of Non-Home Discharge
Patients admitted from the community who are hospitalized with Clostridioides (formerly Clostridium) difficile infection were more frequently discharged to a non-home location compared to patients without C difficile infection.
Want to read more?
Please login or register first to view this content.
Next post in Clostridioides Difficile
